[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-study-detail:100618505":3},{"organization":4,"armGroups":7,"interventions":19,"overallOfficials":12,"centralContacts":23,"locations":29,"responsibleParty":61,"collaborators":12,"id":65,"slug":66,"hasResults":67,"nctId":68,"briefTitle":69,"officialTitle":69,"acronym":70,"eligibilityCriteria":71,"healthyVolunteers":67,"sex":72,"minAge":73,"maxAge":74,"enrollmentInfo":75,"targetDuration":12,"studyType":78,"phases":79,"briefSummary":81,"conditions":82,"keywords":12,"overallStatus":85,"whyStopped":12,"lastUpdateSubmitDate":86,"lastUpdatePostDateStruct":87,"startDateStruct":90,"completionDateStruct":92,"leadSponsor":94,"locationsCount":95},{"fullName":5,"class":6},"Beijing Anzhen Hospital","OTHER",[8,13],{"label":9,"type":10,"description":11,"interventionNames":12},"Usual care Group","NO_INTERVENTION","Patients receive standard post-PCI management, including guideline-directed medical therapy (GDMT) and routine outpatient follow-up visits at 1, 3, 6, 9, and 12 months.",null,{"label":14,"type":15,"description":16,"interventionNames":17},"Digital Remote Management Group","EXPERIMENTAL","1-year intervention:\n\n1. BP Management: Protocol-driven self-monitoring frequencies. The system triggers alerts for BP \\>130\u002F80 mmHg and generates automated suggestions for medication titration, subject to physician approval.\n2. Lipid Management: Automated reminders for laboratory testing. Optical Character Recognition (OCR) technology extracts data from lab reports. If LDL-C ≥1.4 mmol\u002FL, the system proposes regimen intensification for physician review.\n3. Exercise Management:Target of ≥6000 steps\u002Fday. Data is synchronized via wearables or smartphones. Inactivity triggers automated behavioral feedback.\n4. Medication Management: Daily app-based reminders and digital \"check-ins.\" Non-adherence triggers automated alerts followed by human intervention if persistent.\n5. Symptom Monitoring: Patient-reported outcomes (e.g., chest pain\u002Fdyspnea) via the App, with automated triage for risk stratification.\n6. Health Education: Push delivery of targeted secondary prevention educational materials.",[18],"Other: Digital Remote Management Group",[20],{"type":6,"name":14,"description":21,"armGroupLabels":22,"otherNames":12},"1-year intervention\n\n1. BP Management: Protocol-driven self-monitoring frequencies. The system triggers alerts for BP \\>130\u002F80 mmHg and generates automated suggestions for medication titration, subject to physician approval.\n2. Lipid Management: Automated reminders for laboratory testing. Optical Character Recognition (OCR) technology extracts data from lab reports. If LDL-C ≥1.4 mmol\u002FL, the system proposes regimen intensification for physician review.\n3. Exercise Management:Target of ≥6000 steps\u002Fday. Data is synchronized via wearables or smartphones. Inactivity triggers automated behavioral feedback.\n4. Medication Management: Daily app-based reminders and digital \"check-ins.\" Non-adherence triggers automated alerts followed by human intervention if persistent.\n5. Symptom Monitoring: Patient-reported outcomes (e.g., chest pain\u002Fdyspnea) via the App, with automated triage for risk stratification.\n6. Health Education: Push delivery of targeted secondary prevention educational materials.",[14],[24],{"name":25,"role":26,"phone":27,"phoneExt":12,"email":28},"DigiCare-CHD Coordinating Center","CONTACT","13810720787","chshma@vip.sina.com",[30,40,45,53],{"facility":27,"status":12,"city":31,"state":12,"zip":12,"country":32,"countryCode":33,"cosmosGeoPoint":34,"geoPoint":39,"contacts":12},"Beijing","China","CN",{"type":35,"coordinates":36},"Point",[37,38],116.39723,39.9075,{"lat":38,"lon":37},{"facility":41,"status":12,"city":31,"state":12,"zip":12,"country":32,"countryCode":33,"cosmosGeoPoint":42,"geoPoint":44,"contacts":12},"Beijing Tongren Hospital, Capital Medical University, Beijing, China",{"type":35,"coordinates":43},[37,38],{"lat":38,"lon":37},{"facility":46,"status":12,"city":47,"state":12,"zip":12,"country":32,"countryCode":33,"cosmosGeoPoint":48,"geoPoint":52,"contacts":12},"The First Affiliated Hospital of Dalian Medical University, Dalian, China","Dalian",{"type":35,"coordinates":49},[50,51],121.60222,38.91222,{"lat":51,"lon":50},{"facility":54,"status":12,"city":55,"state":12,"zip":12,"country":32,"countryCode":33,"cosmosGeoPoint":56,"geoPoint":60,"contacts":12},"The First Hospital of Jilin University, Changchun, China","Jilin City",{"type":35,"coordinates":57},[58,59],126.5608,43.84652,{"lat":59,"lon":58},{"type":62,"investigatorFullName":63,"investigatorTitle":64,"investigatorAffiliation":5,"oldNameTitle":12,"oldOrganization":12},"PRINCIPAL_INVESTIGATOR","Chang sheng Ma","Director of cardiology department","100618505","digital-remote-management-for-care-and-continuous-optimization-versus-usual-care-in-patients-with-coronary-heart-disease-digicare-chd-100618505",false,"NCT07332494","Digital Remote Management for Care and Continuous Optimization Versus Usual Care in Patients With Coronary Heart Disease (DigiCare-CHD)","DigiCare-CHD","Inclusion Criteria:\n\n1. Age 18-75 years\n2. Diagnosis of Acute Coronary Syndrome (ACS) or Chronic Coronary Syndrome (CCS)\n3. Status post-successful percutaneous coronary intervention (PCI).\n4. Possession of a smartphone and ability to operate the application (independently or with caregiver assistance).\n5. Provision of written informed consent.\n\nExclusion Criteria:\n\n1. Heart Failure: NYHA Class III-IV or LVEF \\\u003C 40%.\n2. Severe hepatic dysfunction (ALT\u002FAST ≥3xULN or Total Bilirubin \\>1.5 mg\u002Fdl)\n3. Severe renal dysfunction (eGFR \\\u003C 30 ml\u002Fmin\u002F1.73m² or requiring dialysis)\n4. Uncontrolled hypothyroidism (TSH \\>1.5xULN or \\>10 mIU\u002FL, or unstable dosage within 6 weeks)\n5. Life expectancy \\\u003C 1 year due to non-cardiovascular comorbidities\n6. Severe sensory (hearing\u002Fvision) or cognitive impairment precluding device use\n7. Conditions affecting adherence (e.g., substance use disorder, history of alcohol abuse)","ALL","18 Years","75 Years",{"count":76,"type":77},792,"ESTIMATED","INTERVENTIONAL",[80],"NA","The DigiCare-CHD study is an investigator-initiated, multicenter, open-label, parallel-group randomized controlled trial. It aims to evaluated the efficacy of a smartphone-based digital remote management platform compared to usual care in achieving dual goal attainment of blood pressure and LDL-cholesterol levels in patients with coronary heart disease following percutaneous coronary intervention.",[83,84],"Coronary Heart Disease","Percutaneous Coronary Intervention","NOT_YET_RECRUITING","2025-12-31",{"date":88,"type":89},"2026-01-12","ACTUAL",{"date":91,"type":77},"2026-01",{"date":93,"type":77},"2027-07",{"name":5,"class":6},4]